Cervical Device Contraception-2 (Nanopaz) (NANOPAZ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00689494|
Recruitment Status : Unknown
Verified June 2008 by Bnai Zion Medical Center.
Recruitment status was: Not yet recruiting
First Posted : June 3, 2008
Last Update Posted : June 3, 2008
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Other: Nanopaz contraception device||Phase 1 Phase 2|
A very small cervical device that releases small amount of progesterone 20 mcgm/day.
The target of the research is to measure blood progesterone by using the cervical device.
This small device delivers progesterone by nanotechnology method.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cervical Device Contraception|
|Study Start Date :||June 2008|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||May 2010|
- Other: Nanopaz contraception device
levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy methodOther Name: levonorgestrel device for cervical contraception-nantechnolgy method
- blood progesterone measure in blood [ Time Frame: one to two months ]